Immune Checkpoint Inhibitors in Lung Cancer

Slides:

Advertisements

Similar presentations

Advancing Care Forward in Squamous Cell Carcinoma of the Head and Neck

Advertisements

Evolving Standards in HER2-Targeted Adjuvant Therapy for Breast Cancer

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

State of the Art in BRCA-Mutated Ovarian Cancer

Immunotherapies: Key Considerations in the Identification and Management of irAEs.

Evolving Paradigms in the Management of HR-Positive Breast Cancer

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Unraveling Clinical Developments in NASH

T-Cell Exhaustion: Can We Overcome It in Cancer?

Advances in Managing Inhibitors in Patients With Hemophilia A

Dual Antiretroviral Therapy

Progression After Cancer Immunotherapy in Advanced NSCLC

New Standards of Care in ALK-Translocated Advanced NSCLC

Mid-Year Hemophilia Update

Induction Chemotherapy for Patients With High-Risk or Secondary AML

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Differentiating Among the CDK 4/6 Inhibitors in the Management of Metastatic Breast Cancer.

The Resurgence of Topical Treatments Across a Spectrum of Psoriasis

Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

Addressing Disease Burden in Asthma

The Evolving Role of Immunotherapy in NSCLC

Immunotherapy in Pancreatic Cancer: Thinking Outside the Box

Optimizing Management of Advanced Bladder Cancer

Addressing Challenges in Factor VIII Inhibitors in Children With Hemophilia.

Advanced Lung Cancers: What's on the Horizon?

The Emerging Role of Immunotherapy in Hodgkin Lymphoma

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Next-Gen Psoriasis Therapies:

Management of CMV in HSCT Recipients

Evaluating Next-Generation BTK Inhibitors

Case Studies in Unresectable Hepatocellular Carcinoma

Gene Therapy: Past, Present, and Future

Therapeutic Approaches to the Management of EDS in OSA

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Ask the Experts.

Immunotherapy for cSCC

Novel Approaches in T1D Management

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

New Data on Emerging Treatments for Psoriasis

When Is Biologic Therapy Appropriate for HS?

Personalizing Management in the Care of Patients With Advanced Sarcoma

Evolving Concepts in the Management of Head and Neck Cancers

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Parkinson Disease Psychosis

Getting to Grips With the Science of CGRP and Migraine

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

Guide to Atopic Dermatitis

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Patient Questions and Expert Answers in Psoriasis:

Biomarker Testing: Harnessing All Sides of the Tumor Microenvironment

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Novel Concepts in the Management of RCC

Debates and Dilemmas, Part 1

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

From Adjuvant to Metastatic in Melanoma

Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

Checkpoint Inhibitors in First-Line Advanced NSCLC

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Presentation transcript:

Immune Checkpoint Inhibitors in Lung Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. Data that we discuss should be considered preliminary until published in a peer-reviewed journal.

Checkpoint Inhibitors Approved for Use in Second-Line Therapy

Checkpoint Inhibitors Approved for Other Uses

KEYNOTE-024

KEYNOTE-189

KEYNOTE-189 (cont)

KEYNOTE-042

IMpower150

IMpower150 Subgroups

CheckMate 227

CheckMate 227 Subgroups

KEYNOTE-407

KEYNOTE-407 Subgroups

IMpower131

Faculty Comments on Front-Line Trials

Patients Taking Baseline Steroids

PACIFIC

Other Trials of Interest From ASCO® 2018

Concluding Remarks

Abbreviations

Abbreviations (cont)